35/100
The participants controlled the EEG Switch above chance level across all tasks. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Dementia is a debilitating disease that leads to a gradual loss of memory and other cognitive abilities and tends to develop in people over 60 years of age. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The early detection of dementia, a condition affecting both individuals and society, is essential for its effective management. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Alzheimer's disease (AD) is recognized as one of the most common neurodegenerative causes of dementia worldwide, having been characterized by progressive cognitive decline for the most part. 2 key findings →
Participants: 461 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Three blood gene expression datasets of high dimensionality and low sample size (HDLSS) have been utilized in this study, with one dataset exhibiting significant class imbalance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 1906, Alois Alzheimer first described the neuropathological hallmarks of the disease that now bears his name. 2 key findings →
Participants: 62 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Early and accurate diagnosis of dementia is essential to improving patient outcomes and reducing societal burden. 1 key finding →
Participants: 164 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For MCI, MoCA cut-offs were 24 (three methods) and 25 (Youden's J Index). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our studies showed that DC and DRs in VD and AD groups were significantly lower than those in controls, while AC values were significantly higher. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The observation group had significantly lower Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) scores than the control group (both P<0.001). 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
DNA methylation, mRNA and protein levels, and cognitive performance using the Mini-Mental State Examination (MMSE) and Clock Drawing Test (CDT). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study (RCT) investigated the impact of Expressive Therapies Continuum (ETC)-based art therapy on cognitive function and quality of life among older adults with dementia living in a complex care setting. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD), the most common form of dementia, is marked by cognitive decline and amyloid-beta (Aβ) plaque deposition in the brain. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association is referred to as DSM-5™. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
34/100
Alzheimer's disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The potential of brain imaging has grown rapidly with new modalities, hybrid combinations of existing modalities, and novel metabolic tracers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The goals of this study were to compare the early diagnostic utility of Alzheimer disease biomarkers in the CSF with those in brain MRI in conditions found in our clinical practice, and to ascertain the diagnostic accuracy of both techniques used together. 4 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Clinical and population-based epidemiological studies report variation in the observed prevalence and incidence of dementia with Lewy bodies (DLB). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study highlights the potential of Decipher‐AI for screening undiagnosed cognitive impairment in primary care. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 739 patients were included: 504 with AD and 235 with non-AD dementias. 5 key findings →
Participants: 739 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
34/100
This study examines the accuracy of CTseg segmentation software to diagnose Alzheimer's disease dementia and other dementias using routine CT scans from a New Zealand memory service. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sex was not a predictor of the total scores of MoCA. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a neurodegenerative disorder characterized by a significant decline in cognitive function. 4 key findings →
Participants: 65 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results indicated good usability for the MoCA Duo. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mean age of the cohort was 77.4 ± 6.8 years, with 62% males and nearly equal urban–rural distribution. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 1,775 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology
- Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease
- Automated remote longitudinal neuropsychological testing with the California Cognitive Assessment Battery
- Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries
- Enhancing Alzheimer’s Diagnosis with Machine Learning on EEG: A Spectral Feature-Based Comparative Analysis
- Use of the QOL-AD for measuring quality of life in people with severe dementia--the LASER-AD study
- Performance of Machine Learning Algorithms for Predicting Progression to Dementia in Memory Clinic Patients
- Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease: The Cognitive Task Force
- Instruments for screening for depression and dementia in a long-term care facility
- Population normative data for the 10/66 Dementia Research Group cognitive test battery from Latin America, India and China: a cross-sectional survey
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →